Join The Community

Summary

The product Tamoxifen, submitted by asteroidbiotech@proton.me, underwent independent testing to verify its composition and potency. The sample, associated with Task Number #52892, was analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control.

The analysis confirmed the presence of Tamoxifen Citrate, with a measured concentration of 19.35 mg. While this result suggests the presence of the expected compound, its dosage may need further comparison with the intended label claim (typically 20 mg per tablet). The testing process was initiated on 21 October 2024, the sample was received on 7 November 2024, and the analysis was completed on 15 November 2024.

Detailed Report

Product Overview

Testing Details

Testing Results

Verification Details

Evaluation of Manufacturer-Submitted Testing

This analysis confirms that the tested Tamoxifen batch contains 19.35 mg of Tamoxifen Citrate, which is slightly below the expected 20 mg dose. While this is within an acceptable margin of error, users should be cautious, as manufacturer-submitted samples may not reflect the quality and consistency of all available batches. Independent third-party testing across multiple batches would provide stronger assurance.

Conclusion

The test results indicate that Tamoxifen contains 19.35 mg of Tamoxifen Citrate, demonstrating a minor variance of -3.25% from the labeled claim. While this suggests quality control is maintained, continued independent analysis is essential for consumer safety and harm reduction.

Disclaimer

This report is published for educational and harm reduction purposes. Manufacturer-submitted tests may contain biases, but they still provide valuable insights when critically analyzed alongside independent third-party results. Readers should use this information responsibly.